RECEPTOR BINDING AND ENZYME ASSAYS USING BIOSOMES TM

使用 BIOSOMES TM 进行受体结合和酶测定

• 批准号: 2544782
• 负责人: CHARLES F SALLER
• 金额: $ 10万
• 依托单位: ANALYTICAL BIOLOGICAL SERVICES, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 1998-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2544782
• 关键词: bioassay; biosensor device; biotechnology; chemical synthesis; colorimetry; dopamine receptor; enzyme substrate; ligands; liposomes; method development; phospholipase A2; receptor binding

The proposed research is aimed at developing a new molecular recognition technology for drug discovery. Stable liposome-based biosensors, called Biosomes TM, turn from blue to red in response to a specific molecular recognition event. The Biosomes can be functionalized with a specific receptor ligand or enzyme substrate so that they respond specifically to a particular receptor or enzyme. Our aim is to develop either a prototypic receptor binding or enzyme assay using the Biosome TM technology in high- throughput screening to detect potential drug leads. In Phase II, this technology will be expanded to additional receptor and enzyme assays of interest to the pharmaceutical industry. These assays will have the advantage of being rapid, homogeneous and non-radioactive. Specifically, we will examine stability and specificity of the Biosomes TM, optimize the assays to detect inhibitors, and determine reproducibility and reliability of the assays. This proposal will enable the development of a new technology which should contribute to the discovery of drugs for a broad range of diseases including psychiatric disorders, inflammatory diseases and cancer. PROPOSED COMMERCIAL APPLICATION: The Proposal is aimed at developing a new technology for drug discovery applications. The -technology should result in rapid high-throughput non- radioactive receptor and enzyme assays with an annual market of over $50,000,000 in the pharmaceutical and biotechnology industries.

拟议的研究旨在开发一种新的分子识别 用于药物发现的技术。稳定的基于脂质体的生物传感器，称为 Biosome TM，对特定分子的反应从蓝色变为红色 表彰活动。生物小体可以用特定的 受体配体或酶底物，以便它们对 一种特殊的受体或酶。我们的目标是开发一款原型车 使用Biosome TM技术进行受体结合或酶分析 吞吐量筛查，以检测潜在的药物先导。在第二阶段，这 技术将扩展到更多的受体和酶分析 引起制药业的兴趣。这些化验将会有 具有快速、均匀和无放射性的优点。具体来说， 我们将检查Biosome TM的稳定性和特异性，优化 检测抑制剂的检测，并确定重复性和可靠性 所有的化验结果。这项提议将使一种新的 技术应该有助于为广泛的药物发现做出贡献 一系列疾病，包括精神障碍、炎症性疾病 和癌症。 建议的商业应用： 该提案旨在开发一种用于药物发现的新技术。 申请。该技术应导致快速、高吞吐量、非 放射性受体和酶分析年市场占有率超过 5,000万美元，用于制药和生物技术行业。